journal
https://read.qxmd.com/read/36999526/plain-language-summary-of-the-development-of-tepotinib-a-treatment-for-a-subtype-of-non-small-cell-lung-cancer%C3%A2-called-met-exon-14-skipping
#1
REVIEW
John Hallick, Anne-Marie Baird, Gerald Falchook, Xiuning Le, David Hong, Santiago Viteri, Jo Raskin, Niels Reinmuth, Soetkin Vlassak, Mihaela Militaru, Paul K Paik
WHAT IS THIS SUMMARY ABOUT?: This plain language summary provides an overview of two of the main clinical studies that led to tepotinib's approval, the phase I first-in-human study and the phase II VISION study. WHAT IS TEPOTINIB?: Tepotinib is a targeted anti-cancer treatment taken orally (by mouth). It is available in many countries for people with advanced or metastatic non-small cell lung cancer (NSCLC), where the tumor contains a genetic mutation (alteration) called ' MET exon 14 skipping'...
March 31, 2023: Future Oncology
https://read.qxmd.com/read/36987975/prognostic-factors-affecting-infantile-medulloblastoma-outcomes%C3%A2-in-the-molecular-era-a%C3%A2-12-year%C3%A2-single-center-experience-from-egypt
#2
JOURNAL ARTICLE
Ahmed El-Hemaly, Moatasem El-Ayadi, Soha Ahmed, Hala Taha, Marwa Said, Amal Refaat, Hany Ammar, Eslam Maher, Eman Badawy, Mohamed Reda, Mohamed El-Beltagy, Mohamed S Zaghloul, Alaa El-Haddad
Aims: To assess the clinical, pathological and molecular characteristics (Sonic hedgehog and group 3/4 molecular subtypes expression) and treatment modalities for infantile medulloblastoma in correlation with outcomes. Materials & methods: A retrospective study of 86 medulloblastoma patients (≤3 years) was conducted. M0 patients <2.5 years received four cycles of chemotherapy followed by focal radiotherapy (FRT) and chemotherapy. Between 2007 and 2015, Metastatic patients <2...
March 29, 2023: Future Oncology
https://read.qxmd.com/read/36987836/brightline-1-phase-ii-iii-trial-of-the-mdm2-p53-antagonist-bi-907828-versus-doxorubicin-in-patients-with-advanced-ddlps
#3
REVIEW
Patrick Schöffski, Mehdi Lahmar, Anthony Lucarelli, Robert G Maki
Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive liposarcoma associated with poor prognosis. First-line treatment for advanced/metastatic DDLPS is systemic chemotherapy, but efficacy is poor and toxicities substantial. Most DDLPS tumors have amplification of the MDM2 gene, which encodes a negative regulator of the p53 suppressor protein. BI 907828 is a highly potent, oral MDM2-p53 antagonist that inhibits the interaction between p53 and MDM2, thereby restoring p53 activity. BI 907828 has shown promising activity in preclinical studies and in a phase Ia/Ib study in patients with solid tumors, particularly those with DDLPS...
March 29, 2023: Future Oncology
https://read.qxmd.com/read/36974621/long-term-outcomes-of-stage-iib-iv-melanoma-patients-nationwide-data-from-norway
#4
JOURNAL ARTICLE
Anna Winge-Main, Trude E Robsahm, Marta Nyakas, Gry Festervoll, Einar Torkilseng, Signe Thybo, Suvendu Pati, Robert Carroll
Aim: This study was performed to investigate the characteristics and overall survival (OS) of patients with completely resected stage IIB-IV cutaneous melanoma identified in the Cancer Registry of Norway. Methods: A retrospective cohort study of all adult patients with stage ≥IIB cutaneous melanoma was performed in Norway (January 2008 to December 2018), excluding patients with stage IV melanoma without evidence of surgery. Results: 5-year OS varied by stage (IIB 65%, IIC 38%, IIIA 79%, IIIB 66%, IIIC 52%, IIID 37% and IV 39%)...
March 28, 2023: Future Oncology
https://read.qxmd.com/read/36974619/neoadjuvant-treatment-and-survival-outcomes-by-pathologic-complete-response-in-her2-negative-early-breast-cancers
#5
JOURNAL ARTICLE
Amanda Crosbie, Trong Kim Le, Ying Zhang, Rolee Das, Felipe Ades, Catherine Davis, Anagha Gogate
Background: The benefit of pathologic complete response (pCR) in early breast cancer (eBC) is not well described in the real-world setting. This study used the nationwide Flatiron Health electronic health record-derived deidentified database to describe treatment patterns and survival outcomes by pCR status after neoadjuvant therapy (NAT) in women with triple-negative or HR+ /HER2- eBC. Materials & methods: Observational cohort study analyzing women with eBC who started NAT between 2011 and 2018. Results: 496 women were included in the study; of those, 16...
March 28, 2023: Future Oncology
https://read.qxmd.com/read/36974606/caregiver-survey-in-glioblastoma-focused-on-cognitive-dysfunction-development-and-results-from-a-multicenter-study
#6
JOURNAL ARTICLE
Trang H Au, Connor Willis, Maija Reblin, Katherine B Peters, Phioanh Leia Nghiemphu, Jennie W Taylor, Howard Colman, Adam L Cohen, David Ryan Ormond, Elizabeth C Neil, Arnab Chakravarti, Nicole Willmarth, Bea Christine Balajonda, Jyothi Menon, Junjie Ma, Hillevi Bauer, Ryan S Nelson, Malinda S Tan, Prianka Singh, Alexander Marshall, Beata Korytowsky, David Stenehjem, Diana Brixner
Aim: This study aimed to develop a cognitive dysfunction (CD) focused questionnaire to evaluate caregiver burden in glioblastoma. Materials & methods: The survey was developed from stakeholder consultations and a pilot study, and disseminated at eight US academic cancer centers. Caregivers self-reported caring for an adult with glioblastoma and CD. Results: The 89-item survey covered demographics, CD symptoms and caregiver burden domains. Among 185 caregivers, most were white, educated females and reported memory problems as the most common CD symptom...
March 28, 2023: Future Oncology
https://read.qxmd.com/read/36974605/relationships-among-clinicians-are-crucial-to-successful-palliative-care-integration-a-qualitative-study-in-lung-cancer
#7
JOURNAL ARTICLE
Donald R Sullivan, Kelly C Vranas, Molly Delorit, Sara E Golden, Christopher G Slatore, Linda Ganzini, Lissi Hansen
Aims: Palliative care integration improves quality of life among patients with lung cancer and their families. Despite these benefits, significant barriers persist and patients do not receive timely integration. This study sought to identify facilitators of and barriers to integration in lung cancer care. Materials & methods: Semistructured qualitative interviews were conducted with palliative care and lung cancer clinicians and analyzed using traditional content analysis. 23 clinicians were interviewed from geographically dispersed hospitals within a national healthcare system...
March 28, 2023: Future Oncology
https://read.qxmd.com/read/36974574/immune-checkpoint-inhibitors-and-carbon-ion-radiotherapy-in-solid-cancers-with-stable-disease-iconic
#8
REVIEW
Stefano Cavalieri, Viviana Vitolo, Amelia Barcellini, Sara Ronchi, Angelica Facoetti, Chiara Campo, Catherine Klersy, Silvia Molinelli, Francesco Agustoni, Virginia Valeria Ferretti, Annalisa De Silvestri, Marco Platania, Michele Del Vecchio, Marco Durante, Alexander Helm, Claudia Fournier, Filippo de Braud, Paolo Pedrazzoli, Ester Orlandi, Lisa Licitra
ICONIC is a multicenter, open-label, nonrandomized phase II clinical trial aiming to assess the feasibility and clinical activity of the addition of carbon ion radiotherapy to immune checkpoint inhibitors in cancer patients who have obtained disease stability with pembrolizumab administered as per standard-of-care. The primary end point is objective response rate, and the secondary end points are safety, survival and disease control rate. Translational research is an exploratory aim. The planned sample size is 27 patients...
March 28, 2023: Future Oncology
https://read.qxmd.com/read/36946253/-kras-g12c-mutation-from-black-sheep-to-key-player-in-pancreatic-cancer-treatment
#9
EDITORIAL
Rebecca Ibrahim, Rita Khoury, Tony Ibrahim, Tarek Assi, Axel Le Cesne
No abstract text is available yet for this article.
March 22, 2023: Future Oncology
https://read.qxmd.com/read/36946237/combi-ted-a-new-trial-testing-tedopi-%C3%A2-with-docetaxel-or-nivolumab-in-metastatic-non-small-cell-lung-cancer-progressing-after-first-line
#10
REVIEW
Lorenza Landi, Angelo Delmonte, Andrea Bonetti, Giulia Pasello, Giulio Metro, Francesca Mazzoni, Gloria Borra, Diana Giannarelli, Kalliopi Andrikou, Daniela Mangiola, Stefania Gori, Mario Rosario D'Andrea, Gabriele Minuti, Blerina Resuli, Anastasia Laudisi, Antonello Vidiri, Laura Conti, Federico Cappuzzo
Despite the positive results obtained by first-line chemoimmunotherapy in patients with metastatic non-small-cell lung cancer (NSCLC), only a few second-line options are available after disease progression. Combi-TED is a phase II international study that will assess the efficacy of Tedopi® , a cancer vaccine, combined with either docetaxel or nivolumab and compared with docetaxel monotherapy in patients with metastatic NSCLC after chemoimmunotherapy. The study, currently in the recruitment phase, will assess 1-year overall survival (primary end point), patient's progression-free survival and overall response rate, as well as the correlation of efficacy with several tumor or blood biomarkers...
March 22, 2023: Future Oncology
https://read.qxmd.com/read/36942803/integrating-radium-223-therapy-into-the-management-of-metastatic-prostate-cancer-care-a-plain-language-summary
#11
REVIEW
Joe M O'Sullivan, Elliot Abramowitz, Len Sierra-Scacalossi
WHAT IS THIS SUMMARY ABOUT?: Few life-prolonging treatment options are available for patients with metastatic castration-resistant prostate cancer (mCRPC). This article provides an overview of the current systemic treatments available for mCRPC and reviews studies that investigate the optimal timing for the use of radium-223. The aim is to illustrate possible systemic treatment sequences to maximize benefit from radium-223 therapy. WHAT IS METASTATIC CASTRATION-RESISTANT PROSTATE CANCER & HOW IS IT TREATED?: Prostate cancer is called mCRPC when it spreads to organs outside of the prostate (such as the lymph nodes, bones, liver, or lungs) and no longer responds to hormonal therapy...
March 21, 2023: Future Oncology
https://read.qxmd.com/read/36942741/extension-of-lymph-node-dissection-in-the-surgical-treatment-of-esophageal-and-gastroesophageal-junction-cancer-seven-questions-and-answers
#12
REVIEW
Alessio Vagliasindi, Filippo Di Franco, Maurizio Degiuli, Davide Papis, Marcello Migliore
The role of two- or three-field nodal dissection in the surgical treatment of esophageal and gastroesophageal junction cancer in the minimally invasive era is still controversial. This review aims to clarify the extension of nodal dissection in esophageal and gastroesophageal junctional cancer. A basic evidence-based analysis was designed, and seven research questions were formulated and answered with a narrative review. Reports with little or no data, single cases, small series and review articles were not included...
March 21, 2023: Future Oncology
https://read.qxmd.com/read/36942735/the-clip1-ltk-fusion-a%C3%A2-new-oncogenic-driver-in-non-small-cell-lung-cancer
#13
EDITORIAL
Rebecca Ibrahim, Claude Chahine, Tony Felefly, Nadine Khalife, Khalil Saleh
No abstract text is available yet for this article.
March 21, 2023: Future Oncology
https://read.qxmd.com/read/36942734/outdoor-air-pollution-and-oral-cancer-critical-viewpoints-and-future-prospects
#14
EDITORIAL
Sachin C Sarode, Gargi S Sarode, Nilesh Sharma
No abstract text is available yet for this article.
March 21, 2023: Future Oncology
https://read.qxmd.com/read/36942686/adverse-events-and-clinical-outcomes-in-patients-treated-with-pd-l-1-blockade-for-advanced-non-small-cell-lung-cancer
#15
JOURNAL ARTICLE
Yan Zhang, Charlotte Doran, Trong Kim Le, Brian Dreyfus, Nina Kola, Brooke E Sylvester, Lincy Lal, John R Penrod, Stephanie Meadows Shropshire
Aims: To describe, in patients with advanced/metastatic non-small-cell lung cancer, the relationship between baseline immunosuppressive drug (ISD)/corticosteroid (CS) use, as well as the incidence of mild/moderate adverse events (AEs), and the clinical effectiveness of PD (L)-1 blockade. Patients & methods: This was a retrospective cohort study of patients with no evidence (n = 131) or positive evidence (n = 269) of ISD/CS use. Results: Duration of treatment, time to next treatment, progression-free survival and overall survival were significantly reduced for patients with evidence of prior ISD/CS use...
March 21, 2023: Future Oncology
https://read.qxmd.com/read/36935643/plain-language-summary-and-patient-perspective-of-the-revised-stars-study-long-term-results-of-a-study-that-compared-the-effectiveness-of-radiotherapy-to-surgery-in-people-with-non-small-cell-lung-cancer
#16
REVIEW
Rachel Jenkins, Joanne Walker, Upal Basu Roy
WHAT IS THIS SUMMARY ABOUT?: This is a summary of a research study called revised STARS. The STARS study involved people with non-small-cell lung cancer, also known as NSCLC. The cancer was less than 5 cm in size and had not spread to other parts of the body (known as stage 1 cancer). The study compared the effectiveness of surgery versus a type of radiotherapy treatment, called stereotactic ablative radiotherapy (also known as SABR) as a treatment for people with NSCLC. Researchers wanted to find out how likely people were to be alive after treatment or if their cancer had grown or spread to other parts of their body (also known as progressed)...
March 20, 2023: Future Oncology
https://read.qxmd.com/read/36935641/2022-cancer-statistics-focus-on-lung-cancer
#17
REVIEW
Rachel Jenkins, Joanne Walker, Upal Basu Roy
WHAT IS THIS SUMMARY ABOUT?: This is a plain language summary of a medical journal article called 'Cancer statistics, 2022'. The data in this summary provides detailed information about lung cancer and less detailed information about other cancers. The researchers from the original study used data gathered from previous years to produce a cancer forecast, predicting the number of new cancer diagnoses and deaths in the United States in 2022. WHAT WERE THE RESULTS?: The review of the data up to 2019 found that compared to previous years: Advanced lung cancer diagnoses had decreased Local stage lung cancer diagnoses had increased Deaths had slowed for lung cancer Deaths continued to reduce for breast cancer, but the rate of this reduction had slowed down Female breast cancer diagnoses were slowly increasing each year Prostate cancer diagnoses stayed similar Local stage prostate cancer diagnoses stayed similar Advanced prostate cancer diagnoses had increased each year The researchers estimated that over 1...
March 20, 2023: Future Oncology
https://read.qxmd.com/read/36935639/plain-language-summary-and-patient-perspective-of-the-american-society-for-clinical-oncology-guideline-management-of-stage-3-non-small-cell-lung-cancer
#18
REVIEW
Rachel Jenkins, Joanne Walker, Upal Basu Roy
WHAT IS THIS SUMMARY ABOUT?: This is a plain language summary of a guideline on the management of stage 3 non-small-cell lung cancer, also known as NSCLC. This guideline was written by the American Society for Clinical Oncology (ASCO for short) and published in the Journal of Clinical Oncology. WHY WERE THE GUIDELINES DEVELOPED?: The purpose of the ASCO guideline is to provide recommendations to healthcare professionals in the US including oncologists, surgeons, pathologists, radiologists, and nurses on how best to diagnose and treat people with stage 3 NSCLC...
March 20, 2023: Future Oncology
https://read.qxmd.com/read/36935637/plain-language-summary-and-patient-perspective-of-the-european-society-for-medical-oncology-expert-consensus-statements-on-treating-egfr-positive-non-small-cell-lung-cancer
#19
REVIEW
Rachel Jenkins, Joanne Walker, Upal Basu Roy
WHAT IS THIS SUMMARY ABOUT?: This article provides a plain language summary and patient perspective of a new set of recommendations made by the European Society for Medical Oncology (ESMO for short). These recommendations are also called expert consensus statements. They cover the management of people with a type of lung cancer called epidermal growth factor receptor-positive non-small-cell lung cancer (EGFR-positive NSCLC for short). WHY WERE THE RECOMMENDATIONS DEVELOPED?: The ESMO Clinical Practice Guidelines are used by healthcare professionals when treating people with cancer, but they don't necessarily have all the information healthcare professionals need to make decisions for with people with EGFR-positive NSCLC...
March 20, 2023: Future Oncology
https://read.qxmd.com/read/36935636/plain-language-summary-and-patient-perspective-of-the-2020-lung-cancer-screening-recommendations-by-the-us-preventive-services-task-force
#20
REVIEW
Rachel Jenkins, Joanne Walker, Upal Basu Roy, Jill Feldman
WHAT IS THIS SUMMARY ABOUT?: This summary describes the research carried out by the United States Preventive Services Task Force (USPSTF for short) during a review and update of their lung cancer screening recommendations made in 2013. The USPSTF reviewed the results of clinical studies that used a type of scan called low dose computed tomography (LDCT for short). They wanted to see how successful LDCT was at finding lung cancers in people ho hadn't shown any physical signs of lung cancer, but had a history of smoking and were over 50 years of age...
March 20, 2023: Future Oncology
journal
journal
41162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.